Results 241 to 250 of about 45,803 (309)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. [PDF]

Diabetes Obes Metab
Tsakiridis EE, Steinberg GR.
europepmc   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control. [PDF]

Rambam Maimonides Med J
Bonga KN, Padhan M.
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Converging Mechanisms, Interactions, and Strategies for Durable Weight Control. [PDF]

Adv Nutr
Wang Y, Liu J, Verbeke K, Retamal NG, Akkerman R, de Vos P.   +5 more
europepmc   +1 more source

Biomimetic MCC950‐loaded cerium‐layered double hydroxide nanoparticles for targeted treatment of Type 1 diabetes in streptozotocin‐induced mice

British Journal of Pharmacology, EarlyView.
The CLMBM nanoparticle (NP) system demonstrates strong and targeted anti‐ROS, antiapoptotic and anti‐inflammatory properties within the pancreas, thereby inhibiting the onset and progression of type 1 diabetes. Background and Purpose The destruction of β‐cells in type 1 diabetes is driven by signalling cascades that ultimately lead to cell apoptosis ...
Huiwen Pang, Zhuo Chen, Youzhi Wu, Thanh‐Truc Nguyen, Jingjing Wang, David M. Klyne, Zhi Ping Xu, Chen Chen, Alan Rowan, Felicity Y. Han   +9 more
wiley   +1 more source

Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review. [PDF]

Curr Obes Rep
Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A.   +4 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source